Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands					12 Months Ended
	Mar. 10, 2022	Apr. 06, 2021	Nov. 09, 2020	Mar. 12, 2020	Dec. 31, 2022	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from Sale of Equity Method Investments	$ 130,000
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs					$ 0	$ 49,744
Net loss					5,005	95,764
Loss from operations					133,281	95,949
Accumulated deficit					$ 429,137	$ 424,132
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings				$ 148,400
Oxford Biomedica plc
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from Sale of Equity Method Investments	50,000
Upfront Payment Received	$ 130,000
Follow On Offering | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares		6,596,306				6,596,306
Shares issued price per share		$ 7.58
Net proceeds after deducting underwriting discounts and commissions and offering expenses		$ 49,700
Common Stock Offering Expenses		$ 300
Underwriters Option | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares		989,445
Shares issued price per share		$ 7.58
ATM
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares					0
Proceeds through future financings					$ 148,400
ATM | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings				$ 150,000
ATM | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares						114,914
ATM | Oxford Biomedica plc
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction	80.00%
ATM | Homology
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction	20.00%
Private Placement
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares			5,000,000
Shares issued price per share			$ 12.00
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs			$ 60,000